Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
STAAR Surgical makes and sells tiny implantable lenses that fix nearsightedness without laser surgery.
STAAR Surgical makes a small, clever product for people who are tired of glasses and contact lenses but don't want laser eye surgery. It sells implantable lenses — tiny, flexible lenses that a surgeon tucks inside the eye, behind the pupil and in front of your natural lens. The lens quietly corrects your vision from the inside, and you can't feel it or see it. The company calls these ICLs, short for implantable collamer lenses, and it also sells the tools surgeons use to put them in.
The customers are eye surgeons, vision centers, and hospitals around the world, and STAAR makes its money selling them the lenses and the delivery systems. The pitch is simple: unlike laser surgery, which permanently reshapes the cornea by removing tissue, an ICL is removable and doesn't destroy anything. That makes it appealing for people with very bad nearsightedness, thin corneas, or dry eyes — folks who aren't great candidates for laser procedures. The big rival is laser vision correction itself, dominated by companies selling excimer lasers, and ordinary glasses and contacts are the real default for most people. STAAR is a small company with big ambitions, and it has been growing fast. Annual revenue climbed to roughly $323 million in 2024, up from around $104 million just five years earlier, as ICL adoption spread, especially in China, which became its largest market by far. The company is based in Lake Forest, California, but its growth story is increasingly an Asian one. It spends heavily on surgeon training and marketing because the procedure only spreads if eye doctors get comfortable recommending it.
The business is not without bruises. Growth stalled in 2024 and 2025 as demand in China softened and competition from cheaper local lens makers intensified, and the stock took a hard hit. STAAR has also been spending on a new manufacturing facility to keep up with expected demand. When it works, the model is beautiful: a high-margin disposable lens, sold again and again as more people get the procedure. When Chinese demand wobbles, though, the whole company feels it — a reminder that a great product can still be a fragile business if too much of it depends on one market.
Saved answer · last researched 16 Nov 2026